We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.
Let the magical night of Christmas Eve bring peace and joy. Let every moment of Christmas live with its own beauty, and bestows the New Year with prosperity and happiness.
On 31st of October 2020, the Chief Sanitary Inspectorate confirmed that the antigen cassette tests are the same basis for determining the SARS-CoV-2 ...
On 26th -27th of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry.
